202127-21-7

Basic information

• Product Name: N,N'-bis(3-methoxyphenyl)-1,3-benzenediamine
• Synonyms: N,N'-bis(3-methoxyphenyl)-1,3-benzenediamine
• CAS NO: 202127-21-7
• Molecular Weight: 320.391
• Mol File: 202127-21-7.mol

Chemical Properties

• CAS DataBase Reference: N,N'-bis(3-methoxyphenyl)-1,3-benzenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-bis(3-methoxyphenyl)-1,3-benzenediamine(202127-21-7)
• EPA Substance Registry System: N,N'-bis(3-methoxyphenyl)-1,3-benzenediamine(202127-21-7)

Safety Data

• Hazardous Substances Data: 202127-21-7(Hazardous Substances Data)

Upstream product

• 2398-37-0 3-methoxyphenyl bromide 
• 108-45-2 m-phenylenediamine 
• 108-36-1 1,3-dibromobenzene 
• 536-90-3 m-Anisidine 

Downstream Products

• 255883-43-3 N,N'-bis(4-bromophenyl)-N,N'-bis(3-methoxyphenyl)-1,3-benzenediamine 
• 67601-15-4 C₁₈H₁₆N₂O₂ 
• 255883-47-7 N,N'-bis{4-(3-methoxyanilino)phenyl}-N,N'-bis(3-methoxyphenyl)-1,3-benzenediamine 

Relevant articles and documents

Tetraazacyclophanes by palladium-catalyzed aromatic amination. Geometrically defined, stable, high-spin diradicals

matrix presented R = R′ =p-Me R = R′ = m-OMe R = R′ = p-OMe R = CO2t-Bu, R′ = p-OMe R = R′ = CO2t-Bu Neutral tetraazacyclophanes were prepared in a one-step palladium-catalyzed amination reaction. Simple oxidation of these materials

Sustainable ppm level palladium-catalyzed aminations in nanoreactors under mild, aqueous conditions

A 1?:?1 Pd?:?ligand complex, [t-BuXPhos(Pd-π-cinnamyl)]OTf, has been identified as a highly robust pre-catalyst for amination reactions leading to diarylamines, where loadings of metal are typically at 1000 ppm Pd, run in water at temperatures between rt and 45 °C. The protocol is exceptionally simple, is readily scaled, and compares very favorably vs. traditional amination conditions. It has also been shown to successfully lead to key intermediates associated with several physiologically active compounds.

COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS

The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy, cerebral amyloid angiopathy, Lewy body disease, dementia, Huntington's disease and prion-based spongiform encelopathy. The invention further provides compounds, methods and pharmaceutical compositions for inhibiting tau protein, Aβ protein or α-synuclein protein aggregation.